Drug repositioning is a highly studied alternative strategy to discover and develop
anticancer drugs. This drug development approach identifies new indications for existing …

Cancer management is major concern of health organizations and viral cancers account for
approximately 15.4% of all known human cancers. Due to large number of patients, efficient …

Increasing costs, much time consumption and high risk of failure associated with the process
of de novo development of new anticancer drugs have prompted the pharmaceutical …

Repurposing is a drug development strategy that seeks to use existing medications for new
indications. In oncology, there is an increased level of activity looking at the use of non …

The subcellular mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) induce
apoptosis in gastric cancer and normal mucosal cells is elusive because of the diverse …

Cancer is a set of extremely complex diseases, which are increasingly prominent today, as it
affects and kills millions of people worldwide, being the subject of intense study both in its …

Drug repurposing is a strategy used to develop new treatments based on approved or
investigational drugs outside the scope of their original clinical indication. Since this …

Ovarian cancer is the seventh most common cancer and the eighth most common cause of
cancer mortality in women. Although standard chemotherapy is the established treatment for …

Drug repurposing is at the heart of precision oncology. The move from tissue-or cancer-
specific treatments to genomic-or actionable-target treatments necessarily entails the reuse …

Our group developed a new model of drug combination consisting of the use of
antineoplastic drugs and different repurposed drugs, having demonstrated that antimalarial …